share_log

Bio-Path Shares Are Trading Higher After the Company Outlined Growing Evidence That Supports the Development of BP1001-A for the Treatment for Obestity and Related Metabolic Disease in Type 2 Diabetes Patients.

Benzinga ·  Dec 11 21:40
Bio-Path Shares Are Trading Higher After the Company Outlined Growing Evidence That Supports the Development of BP1001-A for the Treatment for Obestity and Related Metabolic Disease in Type 2 Diabetes Patients.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment